InnoCare Pharma Ltd
HKEX:9969
Intrinsic Value
InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. [ Read More ]
The intrinsic value of one
InnoCare Pharma Ltd
stock under the Base Case scenario is
6.91
HKD.
Compared to the current market price of 4.45 HKD,
InnoCare Pharma Ltd
is
Undervalued by 36%.
InnoCare Pharma Ltd's market capitalization is 7.9B HKD.
InnoCare Pharma Ltd stock price is 4.45 HKD.
InnoCare Pharma Ltd stock price (4.45 HKD) is 36% less than its Intrinsic Value (6.91 HKD).
InnoCare Pharma Ltd stock (2.2 HKD) is 51% less than its price (4.45 HKD). Open DCF Valuation
InnoCare Pharma Ltd stock price (4.45 HKD) is 62% less than its Relative Value (11.63 HKD). Open Relative Valuation
InnoCare Pharma Ltd has upside potential of 60% compared to the average analyst price target.
Open Wall St Estimates
InnoCare Pharma Ltd's Revenue is forecast to grow at a rate of 28% per year over the next 3 years.
InnoCare Pharma Ltd's Revenue has dropped by 40% over the past 12 months.
InnoCare Pharma Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -12%.
InnoCare Pharma Ltd has negative Operating Income for the last twelve months.
InnoCare Pharma Ltd has negative Net Income for the last twelve months.
InnoCare Pharma Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -63%.
InnoCare Pharma Ltd has negative three-year average ROE (Return on Equity): -4%. The company is not efficient at transforming stockholders' equity into net income.
InnoCare Pharma Ltd has positive Gross Profit for the last twelve months.
InnoCare Pharma Ltd has negative Free Cash Flow for the last twelve months.
InnoCare Pharma Ltd's long-term assets (10B CNY) exceed its long-term liabilties (3B CNY).
InnoCare Pharma Ltd's D/E (Debt to Equity) is very low and is equal to 0.
InnoCare Pharma Ltd has negative three-year average ROIC (Return on Invested Capital): -21%. The company is not efficient at using invested capital to generate operating income.
InnoCare Pharma Ltd's short-term assets (9B CNY) exceed its short-term liabilties (2B CNY).
InnoCare Pharma Ltd has negative Net Debt. This means that the company has more cash and short-term investments (9B CNY) than debt (35m CNY).
InnoCare Pharma Ltd's Altman Z-Score is very high and is equal to 4.3.
Valuation Backtest
InnoCare Pharma Ltd
Run backtest to discover the historical profit from buying and selling
InnoCare Pharma Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
InnoCare Pharma Ltd
Balance Sheet Decomposition
InnoCare Pharma Ltd
| Current Assets | 9.3B |
| Cash & Short-Term Investments | 9.1B |
| Receivables | 144.6m |
| Other Current Assets | 101.4m |
| Non-Current Assets | 1B |
| Long-Term Investments | 11.7m |
| PP&E | 696.5m |
| Intangibles | 276.3m |
| Other Non-Current Assets | 44.6m |
| Current Liabilities | 2.1B |
| Accounts Payable | 118.6m |
| Accrued Liabilities | 57m |
| Other Current Liabilities | 1.9B |
| Non-Current Liabilities | 664m |
| Long-Term Debt | 35.4m |
| Other Non-Current Liabilities | 628.6m |
Earnings Waterfall
InnoCare Pharma Ltd
|
Revenue
|
625.4m
CNY
|
|
Cost of Revenue
|
-143.4m
CNY
|
|
Gross Profit
|
482m
CNY
|
|
Operating Expenses
|
-1.2B
CNY
|
|
Operating Income
|
-730.9m
CNY
|
|
Other Expenses
|
-155.7m
CNY
|
|
Net Income
|
-886.6m
CNY
|
Free Cash Flow Analysis
InnoCare Pharma Ltd
Profitability Score
Profitability Due Diligence
InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
InnoCare Pharma Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
InnoCare Pharma Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Score
InnoCare Pharma Ltd's solvency score is 84/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
InnoCare Pharma Ltd
According to Wall Street analysts, the average 1-year price target for
InnoCare Pharma Ltd
is 7.12 HKD
with a low forecast of 6.91 HKD and a high forecast of 7.48 HKD.
Shareholder Return
Price
InnoCare Pharma Ltd
| Average Annual Return | 15.01% |
| Standard Deviation of Annual Returns | 22.57% |
| Max Drawdown | -87% |
| Market Capitalization | 7.9B HKD |
| Shares Outstanding | 1 764 321 452 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
InnoCare Pharma Ltd
Country
Industry
Market Cap
Dividend Yield
Description
InnoCare Pharma Ltd. is a clinical-stage biopharmaceutical company. The company is headquartered in Beijing, Beijing. The company went IPO on 2020-03-23. The firm discovers, develops and commercializes potentially best-in-class and first-in-class drugs for the treatment of cancer and autoimmune diseases. The firm builds a fully integrated biopharmaceutical platform with strong in-house research and development capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.
Contact
IPO
Employees
Officers
The intrinsic value of one
InnoCare Pharma Ltd
stock under the Base Case scenario is
6.91
HKD.
Compared to the current market price of 4.45 HKD,
InnoCare Pharma Ltd
is
Undervalued by 36%.
You don't have any saved screeners yet
